Aichi Cancer Center Hospital ( Site 2202)

Nagoya, Aichi-ken 464-8681

0 studies enrolling now · 1 studies all time

What they study most

Triple Negative Breast Neoplasms

Studies at this site

• Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After Induction With First-Line Chemotherapy Plus Pembrolizumab in Triple Negative Breast Cancer (TNBC) (MK-7339-009/KEYLYNK-009) — Completed